T2DM
Conditions
Brief summary
The purpose of this study is to investigate the effect of THR-1442 compared to Dapagliflozin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Detailed description
Approximately 390 subjects with inadequately controlled T2DM on metformin were to be recruited from China. Subjects were randomly assigned to receive THR-1442 tablet, 20 mg, or Dapagliflozin tavlet,10 mg, in a ratio of 1:1 once daily for 24 weeks. Subjects were to continue taking metformin for the duration of the study.
Interventions
DRUGTHR-1442 and Dapagliflozin placebo
THR-1442 tablets 20mg and Dapagliflozin tablets placebo
DRUGDapagliflozin 10mg and THR1442 placebo
Dapagliflozin tablets 10mg and THR-1442 tablets placebo
Sponsors
Newsoara Biopharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Dapagliflozin tablets, 10mg; Double Blind; Each subject will receive Dapagliflozin (active tablet) once daily for the duration of the study.
Intervention model description
THR-1442 tablets, 20 mg; Double-Blind; Each subject will receive THR-1442, 20 mg once daily for the duration of the study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female adult subjects ≥ 18 years of age 2. If subjects are female of childbearing potential, subjects must be negative on the pregnancy test and abstain from coitus or use effective contraceptive measures during the entire study until 30 days after the investigational product is discontinued 3. Subjects diagnosed with T2DM, with a HbA1c level of 7.5-11% (inclusive) at screening and 7.0-10.5% (inclusive) at enrollment 4. Subjects who are treated with a stable dose of ≥ 1500 mg/day metformin monotherapy along with diet and exercise counseling for at least 8 weeks prior to screening 5. Subjects with a BMI of 19-35kg/m2 (inclusive) at screening 6. If applicable, taking stable doses of treatment for dyslipidemia and/or hypertension for 30 days prior to screening. Subjects who do not need to be treated with dyslipidemia or hypertension by the investigator's judgment are also eligible for the study
Exclusion criteria
1. History of diabetes insipidus 2. Definitive diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young (MODY), or secondary diabetes mellitus 3. Symptoms of diabetes mellitus inadequate control, resulting in the inability to participate in this trial, including but not limited to significant polyuria and polydipsia within 3 months prior to the screening visit and weight loss \> 10% 4. History of urinary tract or genital infection within 6 months prior to screening, or ≥ 3 times of urinary tract or genital infections within 6 months prior to screening that require treatments 5. Two or more consecutive SMBG measures ≥ 250 mg/dL (13.9 mmol/L) prior to randomization (run-in period) accompanied by clinical signs or symptoms of hyperglycemia prior to randomization, including weight loss, blurred vision, increased thirst, increased urination, or fatigue 6. History of diabetic ketoacidosis or hyperosmolar non-ketonic coma within 6 months prior to screening 7. History of severe fracture secondary to osteoporosis 8. Poorly controlled hypertension: blood pressure systolic ≥ 160 mmHg and/or blood pressure diastolic ≥ 100 mmHg 9. Surgical history resulting in unstable weight or scheduled for such surgery during the study period 10. Any unstable endocrine, psychiatric, or rheumatoid disease as assessed by the investigator 11. Possible risk of dehydration or body fluid exhaustion based on the investigator's judgment that may affect the interpretation of efficacy or safety data 12. Currently having or had a history of alcohol or drug abuse within the past 6 months 13. Presence of the following cardiovascular/vascular disorders within 6 months prior to screening: 14. Unstable or rapidly progressive renal disorder 15. Congenital renal glycosuria 16. Major liver disease, including but not limited to hepatitis chronic active and/or significant hepatic function abnormal, including ALT and/or AST ≥ 3 × upper limit of normal (ULN) and/or total bilirubin ≥ 2 × ULN; or medical history of severe hepatobiliary disease; or history of any drug-related hepatotoxicity; 17. Current positive serological test result for infectious hepatitis, including known positivity to hepatitis B surface antigen and hepatitis C antibody
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in HbA1c at Week 24 | Baseline to week 24 | HbA1c was obtained at baseline and at Week 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in FPG at Week 24 | Baseline, up to 24 weeks | FPG was obtained at baseline and at Week 24 |
| Change in Body Weight From Baseline to Week 24 | Baseline, up to 24 weeks | Body Weight was obtained at baseline and at week 24 |
| Changes in blood pressure from baseline to week 24 | Baseline, up to 24 weeks | Blood pressure was obtained at baseline and at week 24 |
Countries
China
Contacts
Primary ContactOwen Zhang
Outcome results
None listed